Comparing the effects of two inhaled glucocorticoids on allergen-induced bronchoconstriction and markers of systemic effects, a randomised cross-over double-blind study

Clinical and Translational Allergy

Peter Arvidsson¹  Mona Palmqvist¹  Jan Lötvall¹ 

[1] Krefting Research Centre, University of Gothenburg, BOX 424, SE 40530 Göteborg, Sweden

关键词: inflammation;    mometasone;    budesonide;    asthma;    allergen;   

Others  :  794766
DOI  :  10.1186/2045-7022-1-12

 received in 2011-08-25, accepted in 2011-10-31,  发布年份 2011

【 摘 要 】

Background

Inhaled glucocorticoids are efficient in protecting against asthma exacerbations, but methods to compare their efficacy vs systemic effects have only been attempted in larger multi-centre studies. The aim of the current study was therefore to directly compare the effects of two separate inhaled glucocorticoids, mometasone and budesonide, to compare the effects on the early and late asthmatic responses to inhaled allergen in patients with mild allergic asthma, and sputum eosinophils, and to relate the clinical positive effects to any systemic effects observed.

Methods

Twelve patients with documented early and late asthmatic responses (EAR and LAR) to inhaled allergen at a screening visit were randomized in a double-blind fashion to treatment with mometasone (200 μg × 2 or 400 μg × 2), budesonide (400 μg × 2) or placebo in a double-blind crossover fashion for a period of seven days. Challenge with the total allergen dose causing both an EAR and LAR was given on the last day of treatment taken in the morning. Lung function was assessed using FEV1, and systemic glucocorticoid activity was quantified using 24 h urinary cortisol.

Results

Mometasone and budesonide attenuate both EAR and LAR to allergen to a similar degree. No significant dose-related effects on the lung function parameters were observed. Both treatments reduced the relative amount of sputum eosinophils (%) after allergen. At the dose of 800 μg daily, mometasone reduced 24 h urinary cortisol by approximately 35%. Both drugs were well tolerated.

Conclusions

Mometasone and budesonide are equieffective in reducing early and late asthmatic responses induced by inhaled allergen challenge. Mometasone 800 μg given for seven days partially affects the HPA axis.

【 授权许可】

   
2011 Lötvall et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Boulet LP, et al.: The allergen bronchoprovocation model: an important tool for the investigation of new asthma anti-inflammatory therapies. Allergy 2007, 62(10):1101-10.
• [2]Cockcroft DW, et al.: Understanding allergic asthma from allergen inhalation tests. Can Respir J 2007, 14(7):414-8.
• [3]de Monchy JG, Aalbers R, Timens W: The clinical relevance of bronchial biopsies in asthma. Respir Med 1993, 87(Suppl B):23-4.
• [4]Lotvall J, Inman M, O'Byrne P: Measurement of airway hyperresponsiveness: new considerations. Thorax 1998, 53(5):419-24.
• [5]Gauvreau GM, et al.: The effects of inhaled budesonide on circulating eosinophil progenitors and their expression of cytokines after allergen challenge in subjects with atopic asthma. Am J Respir Crit Care Med 2000, 162(6):2139-44.
• [6]Tivenius L, Kiviloog J, Glennow C: Effect of budesonide inhalation on airway obstruction at bronchial allergen provocation after varying lengths of pre-treatment. Allergy 1984, 39(8):639-40.
• [7]O'Shaughnessy KM, et al.: Differential effects of fluticasone propionate on allergen-evoked bronchoconstriction and increased urinary leukotriene E4 excretion. Am Rev Respir Dis 1993, 147(6 Pt 1):1472-6.
• [8]Palmqvist M, et al.: Differential effects of fluticasone and montelukast on allergen-induced asthma. Allergy 2005, 60(1):65-70.
• [9]Inman MD, et al.: Dose-dependent effects of inhaled mometasone furoate on airway function and inflammation after allergen inhalation challenge. Am J Respir Crit Care Med 2001, 164(4):569-74.
• [10]Gauvreau GM, et al.: Effect of low-dose ciclesonide on allergen-induced responses in subjects with mild allergic asthma. J Allergy Clin Immunol 2005, 116(2):285-91.
• [11]Pin I, et al.: Use of induced sputum cell counts to investigate airway inflammation in asthma. Thorax 1992, 47(1):25-9.
• [12]Pizzichini MM, et al.: Spontaneous and induced sputum to measure indices of airway inflammation in asthma. Am J Respir Crit Care Med 1996, 154(4 Pt 1):866-9.
• [13]Pizzichini E, et al.: Indices of airway inflammation in induced sputum: reproducibility and validity of cell and fluid-phase measurements. Am J Respir Crit Care Med 1996, 154(2 Pt 1):308-17.
• [14]Pizzichini E, et al.: Measurement of inflammatory indices in induced sputum: effects of selection of sputum to minimize salivary contamination. Eur Respir J 1996, 9(6):1174-80.
• [15]Inman MD, et al.: The utility of methacholine airway responsiveness measurements in evaluating anti-asthma drugs. J Allergy Clin Immunol 1998, 101(3):342-8.
• [16]Inman MD, et al.: Reproducibility of allergen-induced early and late asthmatic responses. J Allergy Clin Immunol 1995, 95(6):1191-5.
• [17]Gauvreau GM, et al.: Repeatability of allergen-induced airway inflammation. J Allergy Clin Immunol 1999, 104(1):66-71.
• [18]Woolley KL, et al.: Effects of allergen challenge on eosinophils, eosinophil cationic protein, and granulocyte-macrophage colony-stimulating factor in mild asthma. Am J Respir Crit Care Med 1995, 151(6):1915-24.
• [19]Botturi K, et al.: Differences in allergen-induced T cell activation between allergic asthma and rhinitis: Role of CD28, ICOS and CTLA-4. Respir Res 2011, 12(1):25. BioMed Central Full Text
• [20]Juniper EF, et al.: Long-term effects of budesonide on airway responsiveness and clinical asthma severity in inhaled steroid-dependent asthmatics. Eur Respir J 1990, 3(10):1122-7.
• [21]Juniper EF, et al.: Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics. Am Rev Respir Dis 1990, 142(4):832-6.
• [22]O'Byrne P: Asthma pathogenesis and allergen-induced late responses. J Allergy Clin Immunol 1998, 102(5):S85-9.
• [23]Parameswaran K, et al.: Protective effects of fluticasone on allergen-induced airway responses and sputum inflammatory markers. Can Respir J 2000, 7(4):313-9.